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Abstract: Primary prophylaxis with the use of an effective and safe intervention appears the 
best approach of venous thromboembolism (VTE) management in medical elderly patients, 
the most affected by VTE. With increasing life expectancy, prevention of VTE, particularly in 
elderly patients, will arise as a major public health problem. Few well designed clinical trials 
evaluating thromboprophylaxis in medical settings were conducted in the speciﬁ  c population 
of geriatric patients. However, among the several pharmacological treatments evaluated, low 
molecular weight heparins enoxaparin 40 mg daily or dalteparin 5000 IU daily appeared effective 
and safe in the prevention of VTE in elderly patients. Despite available data, and recommenda-
tions for VTE prevention in medical patients, thromboprophylaxis is underused or misused in 
practice. Heterogeneity of clinical studies, selected populations, concern about bleeding, and 
lack of a clear clinical beneﬁ  t are some of the reasons that could explain the gap between theory 
and practice. In this review, after a brief report of epidemiologic data and speciﬁ  cities of VTE 
in elderly patients, the authors discuss the available results of VTE primary prevention trials 
for elderly medical patients, the limitations of these data, and the challenges to improve the 
practice and to reduce the incidence of this frequent but preventable disease.
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Introduction
Venous thromboembolism (VTE) is a major cause of morbidity and mortality in 
hospitalized patients (Anderson et al 1991). Risk of VTE associated with surgical 
procedures is well established, and the beneﬁ  t of thromboprophylaxis has been clearly 
demonstrated in surgical settings (Geerts et al 2004). Use of thromboprophylaxis is 
now a routine practice in patients undergoing surgery. However, recent epidemiological 
data suggested that the majority of VTE events acquired in hospitals occurred in 
medical, rather than in surgical patients (Lindblad et al 1991). Despite this, prevention 
of  VTE in medical settings has been less extensively studied than in surgical settings. 
Nevertheless, some good-quality clinical trials have been conducted in the last decade 
in hospitalized medical patients, and guidelines now exist for these patients. Con-
sensus guidelines published by the American College of Chest Physicians (ACCP) 
recommend prophylaxis with unfractionated heparin (UFH) or low molecular weight 
heparin (LMWH) in patients admitted to hospital with congestive heart failure or severe 
respiratory disease, or who are conﬁ  ned to bed and have one or more additional risk 
factors, including active cancer, previous VTE, sepsis, acute neurological disease, or 
inﬂ  ammatory bowel disease (Geerts et al 2004).
Among medical patients, elderly patients deserve probably more attention 
than others as regards the risk and the prevention of VTE for many reasons. They 
are more affected by VTE than younger patients (Oger 2000); the proportion 
of severe and fatal VTE events is higher in those patients (Heit et al 2001); the 
association with other comorbidities is frequent (Knifﬁ  n et al 1994); diagnosis of Clinical Interventions in Aging 2008:3(3) 400
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pulmonary embolism (PE) is more difﬁ  cult (Le Gal et al 
2005; Righini et al 2005); and ﬁ  nally the risk of bleeding 
related to anticoagulant treatments is high (Lopez-Jimenez 
et al 2006), even more due to the high frequency of poly-
medication and interaction between used drugs. Therefore, 
prevention of VTE in this speciﬁ  c population is particularly 
challenging.
Despite relative high proportion of elderly patients 
included in the largest recent clinical trials of   VTE 
prevention in medical settings (Samama et al 1999; 
Leizorovicz et al 2004; Cohen et al 2006), none were 
speciﬁ  cally conducted in the elderly population, and only a 
few other large, well designed, randomized controlled trials 
have been performed addressing this speciﬁ  c issue (Dahan 
et al 1986; Bergmann and Caulin 1996). Nevertheless 
some data from these studies are available for elderly 
patients and are discussed in this review. However, speciﬁ  c 
concerns, such as bleeding risk or lack of clinical beneﬁ  t 
remain, and could explain why the systematic use of pro-
phylaxis in elderly is not well implemented in medical 
wards (Anderson et al 2003).
After a report of VTE epidemiology and speciﬁ  cities in 
elderly medical patients, this review gives some practical 
advice, based on available data, to manage VTE prevention 
in older patients in medical wards. We also discuss the limits 
of current data and the challenges to improve the practice and 
reduce the incidence of VTE in elderly patients.
Venous thromboembolism 
in elderly medical patients
VTE: a disease of elderly patients
The incidence of   VTE increases with age. A population-
based study of patients discharged from hospital showed that 
the incidence of deep venous thrombosis (DVT) increased 
from 119 per 100,000 patients between 60–69 years old, 
to 291 per 100,000 patients 80 years old (Anderson et al 
1991). In France, the global annual incidence of symptomatic 
VTE was 1.83 per 1000 patients, but reached 10 per 1000 
patients aged 75 years or older (Oger 2000). The increased 
incidence was noted for DVT, but also for PE. Moreover, 
because of the silent nature of the disease, the incidence of 
VTE was probably underestimated.
In a post-hoc analysis of MEDENOX study, age 75 
years was found to be an independent risk factor of VTE 
(Alikhan et al 2004), and prevalence of VTE reached 18% in 
patients 75 years old from the placebo group (Alikhan et al 
2003). Furthermore, elderly patients have often other acquired 
conditions recognized as risk factors for VTE that contribute 
to the high incidence of the disease (Knifﬁ  n et al 1994).
High mortality rate in elderly patients
The mortality of acute VTE in elderly is increased: 16% 
of patients over 80 years died early after the diagnosis of 
VTE, in comparison with 2% before 40 years, a difference 
that is conﬁ  rmed and increased over 3.5 years of follow up 
(Anderson et al 1991). In the analysis of the RIETE registry, 
at three months after the venous thromboembolic event, 
3.7% of patients aged 80 years died of PE compared to 
1.1% of patients 80 years (OR 3.6, 95% CI 2.7–4.7) 
(Lopez-Jimenez et al 2006).
More severe initial presentation 
in elderly patients
In the study by Heit and colleagues (2001), there is a trend of 
a higher proportion of symptomatic PE in elderly: in patients 
over 70 years, PE is the manifestation of VTE in 70% of 
cases, in comparison with 55% of cases under 70 years. 
This ﬁ  nding is conﬁ  rmed in the RIETE registry, where 
patients 80 years old were more often enrolled with symp-
tomatic PE (Lopez-Jimenez et al 2006). In this study, patients 
with VTE aged 80 or over more often weighed 65 kg, and 
had a higher rate of chronic lung disease, heart failure and 
creatinine clearance 60 mL/ min.
Difﬁ  culties of diagnosis 
of PE in elderly patients
Clinical symptoms and sign of PE are not speciﬁ  c, and PE 
can be a silent disease as well. Sometimes sudden death is 
the ﬁ  rst clinical manifestation of PE. In autopsy studies, 
diagnosis of PE was suspected before death in only 10% of 
patients who died from proven PE (Sandler and Martin 1989). 
Diagnosis of PE is particularly difﬁ  cult in elderly patients 
because the clinical presentation is less discriminative. The 
frequency of many cardiopulmonary underlying conditions 
that may mimic clinical presentation of PE is increased 
with age, and on the other hand, some classical signs of 
PE such as hemoptysis, tachycardia, hemidiaphragmatic 
elevation and pleural effusion were not associated with PE 
in patients aged 75 years or over (Le Gal et al 2005). The 
characteristics of diagnostic tests for PE are also unfavor-
ably inﬂ  uenced by age (Righini et al 2005). In a study of 
1029 consecutive patients presenting to the emergency 
department with clinically suspected PE, this diagnosis could 
be ruled out by a negative D-dimer test in 67% of patients 
40 years or under, but in only 10% of patients aged 80 years Clinical Interventions in Aging 2008:3(3) 401
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or older (Righini et al 2000). Lung scan for PE diagnosis 
demonstrates a lower performance in elderly due to frequent 
underlying pulmonary diseases (Righini et al 2000), and 
ﬁ  nally, the frequency of renal impairment in elderly patients 
limits the use of CT-scan.
High bleeding risk in elderly patients
The main risk of treatment with anticoagulants, at therapeutic 
or prophylactic doses, is bleeding. Major data on the risk of 
bleeding is provided by trials on long term oral anticoagu-
lation. These studies have shown that elderly patients with 
VTE have a higher risk of bleeding complications (Landefeld 
and Beyth 1993; White et al 1999; Levine et al 2001). In a 
prospective evaluation of an index for predicting the risk of 
major bleeding in outpatients treated with warfarin, age 65 
years or greater was found to be an independent risk factor 
of major bleeding (Beyth et al 1998). In an analysis from 
the RIETE registry (Lopez-Jimenez et al 2006), 3.4% of 
patients 80 years old had major bleeding events compared 
to 2.1% of patients 80 years. Fatal bleeding occurred in 
0.8% in the oldest and 0.4% among patients 80 years. 
Recent bleeding, abnormal renal function (creatinine clear-
ance 60 mL/min), use of corticosteroids or long term 
therapy with LMWH were independently associated with an 
increased risk of major bleeding. Other results from the same 
registry have also shown that major and fatal bleeding events 
occurred more frequently in acutely ill medical patients than 
in surgical patients (Monreal et al 2004).
In the case of severe renal insufﬁ  ciency, UFH can be 
used, while LMWH are usually contraindicated. However, 
UFH was also associated with a higher risk of bleeding in 
the elderly (Campbell et al 1996).
During VTE prophylaxis, results from a meta-analysis 
of clinical trials conducted in medical settings showed that 
the incidence of major bleeding was 0.4% in heparin groups, 
compared to 0.2% in control groups (Mismetti et al 2000). In 
the recent trials, this incidence varied from 0.2% to 1.7% in 
the treatment groups (Samama et al 1999; Leizorovicz et al 
2004; Cohen et al 2006).
VTE: a complication of medical illness
VTE is a major cause of morbidity and mortality in 
hospitalized patients (Anderson et al 1991). It has been 
reported that 10% of deaths occurring during hospitalization 
were related to PE (Sandler and Martin 1989). Autopsy 
studies revealed that 70% to 80% of all in-hospital deaths 
related to PE were not associated with surgical procedures, 
but occurred in medical patients (Goldhaber et al 1983; 
Sandler and Martin 1989; Lindblad et al 1991; Baglin et al 
1997). Hospitalization for an acute medical illness was also 
recognized as an independent factor of VTE associated 
with about an 8-fold increased relative risk for VTE (Heit 
et al 2000). Moreover, the initial presentation and outcomes 
of VTE were more severe and frequent in patients who 
developed VTE after an acute medical illness than in patients 
who developed VTE after a surgical intervention (Monreal 
et al 2004).
Before the publication of the more recent large clinical 
trials, the incidences of DVT (including asymptomatic DVT) 
and clinical PE in medical patients not receiving prophylaxis 
were respectively estimated at about 19% and 1% (Mismetti 
et al 2000). Results from recent large clinical trials for 
VTE incidence rates in placebo groups were: 15% in the 
MEDENOX study (Samama et al 1999), 5% in PREVENT 
study (Leizorovicz et al 2004), and 11% in ARTEMIS study 
(Cohen et al 2006). Differences in asymptomatic outcomes 
deﬁ  nition (proximal alone or distal and proximal DVT), 
and methods to measure these outcomes (venography or 
compression ultrasonography) could explain this relatively 
wide interval for incidence rates.
Among hospitalized patients, elderly medical patients 
are probably the most affected by VTE. As a result, the 
proportion of preventable events by an effective thrombopro-
phylaxis is expected to be high in this population. Moreover, 
because of VTE speciﬁ  cities in elderly (high mortality rate, 
severe initial presentation, difﬁ  cult diagnosis of PE and high 
risk of major bleeding with anticoagulant drugs at therapeutic 
doses), primary prophylaxis with the use of an effective and 
safe intervention appears to be the best approach to VTE 
management.
Management of thromboprophylaxis 
in elderly medical patients
Do all hospitalized elderly medical 
patients need a thromboprophylaxis?
The ﬁ  rst question in front of a newly admitted elderly patient 
is whether they will require prevention against VTE; in other 
words, we have to systematically assess the individual risk 
of venous thrombosis, and select the patients for whom 
thromboprohylaxis would be helpful.
This assessment, and therefore the decision of prescribing 
a prophylaxis, should be based on the presence or absence 
of speciﬁ  c risk factors (Table 1). Previous studies have 
identiﬁ  ed a number of risk factors for VTE in medical 
patients (Anderson et al 1991; Samama 2000; Heit et al 2001; Clinical Interventions in Aging 2008:3(3) 402
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Heit et al 2002; Arcelus et al 2003). Many of these factors are 
frequent in elderly hospitalized patients, alone or combined 
and generally cumulative (Knifﬁ  n et al 1994; Rosendaal 
1999). However, individual risk assessment in medical 
settings can be problematic in practice.
In clinical trials on thromboprophylaxis in medical settings, 
eligibility criteria included most of the various risk factors 
(Table 2) but they differ between studies and cannot be easily 
repeated (Samama et al 1999; Leizorovicz et al 2004; Cohen 
et al 2006). Thromboprophylaxis has been studied speciﬁ  cally 
in some medical conditions such as stroke (Kamphuisen and 
Agnelli 2007; Sherman et al 2007), myocardial infarction (Pitt 
et al 1980) or cancer (Levine et al 1994; Kakkar et al 2004). 
Instead of providing clariﬁ  cation, the decision of whom and 
how to treat may become more difﬁ  cult as a result.
Nevertheless, assessment of the risk of VTE is 
probably easier for elderly than for other medical patients. 
Because age over 75 years is an independent risk factor 
of VTE in medically ill patients (Alikhan et al 2004), the 
presence of only one additional acute medical condition 
is required to consider thromboprophylaxis for these 
patients, using for example the risk assessment model 
developed by Cohen and colleagues (2005). A throm-
boprophylaxis should be proposed if the hospitalization 
is motivated by one of these following conditions: acute 
myocardial infarction, acute heart failure, active cancer 
requiring therapy, acute infectious disease, respiratory 
disease, acute rheumatologic disease, ischemic stroke, 
paraplegia, and inﬂ  ammatory disorder with immobility 
or inﬂ  ammatory bowel disease.
Table 1 Risk factors of venous thromboembolism in medical patients
Permanent underlying risk conditions Acute medical conditions Iatrogenic risk factors
Advanced age (75 years) Heart failure Hormone replacement therapy
History of   VTE Severe respiratory diseases Hospital or nursing home conﬁ  nement
Varicose veins Acute infectious diseases
Obesity Malignancy Chemotherapy
Malignancy Stroke Central venous catheter
Thrombophilia Prolonged immobilization (3 years)
Myocardial infarction
Table 2 Eligibility criteria in MEDENOX, PREVENT, and ARTEMIS clinical trials
MEDENOX PREVENT ARTEMIS
Age  40 years Age  40 years Age  60 years
–  Expected hospital stay 6 days –  Expected hospital stay 4 days –  Expected bed rest 4 days
–  Recent immobilization (3 days) –  Recent immobilization (3 days) –  Congestive heart failure (NYHA
–   Congestive heart failure (NYHA III/IV) or acute 
respiratory failure, or one medical condition if 
associated with at least one additional risk factor 
of   VTE.
–  Congestive heart failure (NYHA III/IV) or acute 
respiratory failure or one medical condition if 
associated with at least one additional risk 
factor of   VTE.
III/IV) or acute respiratory illness in 
the presence of chronic lung disease, 
or clinically diagnosed acute infections 
or inﬂ  ammatory disorders such as 
arthritis, connective tissue diseases, or 
inﬂ  ammatory bowel disease.
Medical conditions were: acute infection 
without septic shock; acute rheumatic disorders, 
including acute lumbar pain or sciatica or vertebral
 compression (caused by osteoporosis or a tumor), 
acute arthritis of the legs, or an acute episode of 
rheumatoid arthritis in the legs, or an episode of 
inﬂ  ammatory bowel disease.
Medical conditions were: infection without 
septic shock, acute rheumatologic disorders, 
or inﬂ  ammatory bowel disease
No other risk factor required
Additional risk factors of   VTE were: age 75 years, 
cancer, previous VTE, obesity, varicose veins, hor-
mone therapy (antiandrogen or estrogen, except for 
postmenopausal hormone-replacement therapy), and 
chronic heart or respiratory failure
Additional risk factors of VTE were: age 75 years, 
cancer, previous VTE, obesity, varicose veins and/or 
chronic venous insufﬁ  ciency, hormone replacement 
therapy, history of chronic heart failure, chronic 
respiratory failure, or myeloproliferative syndrome.Clinical Interventions in Aging 2008:3(3) 403
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In conclusion, elderly medical patients should receive a 
thromboprophylaxis if an acute medical illness is the leading 
cause of hospitalization.
Which prophylaxis should be used?
Among thromboprophylactic methods, anticoagulant 
treatments with UFH or LMWH are the regimens of choice, 
but they share main contraindications: untreated hemophilia 
and other hemorrhagic disorder, active bleeding or perceived 
bleeding risk ( peptic ulcer, recent cerebral hemorrhage, severe 
hypertension, and severe liver disease), thrombocytopenia 
with platelets 60 × 109/L, a history of heparin-induced 
thrombocytopenia, and hypersensitivity to heparin.
Because of its principally renal route of elimination, 
LMWH, even at prophylactic doses, must be used with 
caution in patients with renal failure. When creatinine 
clearance is less than 30 mL/min, UFH may be preferred.
Before prescribing an anticoagulant regimen, we need to 
check systematically the potential contraindications: base-
line risk of bleeding, platelets count and renal function. In 
the event that there is a contraindication to pharmacological 
thromboprophylaxis, consider nonpharmacological treat-
ments. Nonpharmacological strategies include graduated 
compression stockings, intermittent pneumatic compression, 
leg elevation, and early mobilization. No randomized clinical 
trials have evaluated mechanical methods of prophylaxis 
in general medical patients. These measures should be 
considered as alternative methods when contraindications 
to anticoagulants exist (Geerts et al 2004).If there is no 
contraindication to pharmacological treatments, use LMWH 
or UFH.
Prophylactic treatment versus placebo (Table 3)
Seven trials comparing a prophylactic heparin treatment 
to a control (15,095 patients) in medical patients were 
selected in the meta-analysis by Mismetti and colleagues 
(2000). Four studies evaluated UFH at 10000 IU or 15000 
IU daily (Belch et al 1981; Cade et al 1982; Ibarra-Perez 
et al 1988; Gardlund 1996) and three studies evaluated 
a LMWH (enoxaparin or nadroparin) (Dahan et al 
1986; Bergmann and Caulin 1996; Fraisse et al 2000). 
A signiﬁ  cant decrease in DVT and in clinical PE were 
observed with heparins as compared to control (risk reduc-
tions of 56% and 58% respectively, p  0.001 in both 
cases), without signiﬁ  cant difference in the incidence of 
major bleedings or deaths.
In the MEDENOX study, patients of 75 years or older 
accounted for more than half of acute ill medical patients 
included in the trial (Samama et al 1999). A post-hoc 
analysis was performed in the subgroup of older patients 
(Alikhan et al 2003). Those who received 40 mg enoxa-
parin had a 78% reduction in VTE when compared with 
placebo (absolute risk reduction 14.4%; relative risk [RR] 
0.22; 95% CI, 0.09–0.51). The incidence of adverse effects, 
including hemorrhages, did not differ signiﬁ  cantly between 
the placebo group and either enoxaparin group in the pri-
mary analysis, but no data were reported for the subgroup 
of elderly patients.
The PREVENT trial included medical patients randomized 
to receive dalteparin, 5000 IU once daily, or placebo 
(Leizorovicz et al 2004). In the subgroup of patients 75 years 
or older, who represented one third of the population included 
in the trial, the primary end point was reported in 4.2% 
with dalteparin and 8.0% with placebo (RR 0.52; 95% 
CI, 0.31–0.87) (Kucher et al 2005b). Dalteparin was not 
associated with a signiﬁ  cant increase in major hemorrhage 
(1.1% vs 0.7%; p = 0.12).
The ARTEMIS study was designed to evaluate the 
efﬁ  cacy and safety of the anticoagulant fondaparinux in 
older acute medical inpatients at moderate to high risk of 
VTE (Cohen et al 2006). To our knowledge, no speciﬁ  c data 
concerning the subgroup of elderly patients were already 
published.
Two double-blind randomized studies evaluated 
thromboprophylaxis without systematic assessment of 
asymptomatic DVT at the end of the treatment period 
(Bergmann and Caulin 1996; Lederle et al 2006). In the 
ﬁ  rst study, nadroparin did not have a signiﬁ  cant effect on 
mortality and the study provided no data suggesting that 
nadroparin may reduce the incidence of thromboembolic 
events in patients hospitalized for an acute medical disease 
(Bergmann and Caulin 1996; Mahe et al 2005). In the second 
study, the primary outcome was the total mortality at 90 days 
after randomization, but authors reported also the number 
of readmission due to objectively proven symptomatic 
venous thromboembolic events occurring within 90 days of 
randomization (Lederle et al 2006). Overall mortality and 
occurrence of clinical thromboembolic events did not differ 
between enoxaparin and placebo.
Comparison of prophylactic 
anticoagulant regimens
A meta-analysis of eight trials comparing UFH and LMWHs 
in medical patients found no signiﬁ  cant differences between 
the two treatment groups on the incidence of DVT, clinical 
PE or mortality (Mismetti et al 2000). However, LMWH Clinical Interventions in Aging 2008:3(3) 404
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seemed to be safer than UFH by reducing the risk of major 
hemorrhage (RR 52%, p = 0.049).
In the recent meta-analysis by Wein et al (2007) that 
included studies of patients with acute ischemic stroke, 
LMWH was associated with a reduced risk of DVT 
(RR, 0.68; 95% CI, 0.52–0.88) and injection site hematoma 
(RR, 0.47; 95% CI, 0.36–0.62) compared with UFH. No 
statistically signiﬁ  cant differences were observed between 
the two treatments with respect to PE, mortality, total 
bleeding, and major or minor bleeding.
Enoxaparin 20 mg once daily and UFH 5000 IU twice 
daily were considered equivalent in terms of efﬁ  cacy in 
patients aged 65 years or more (mean age 83 years) and no 
signiﬁ  cant difference was found in terms of safety (Bergman 
and Neuhart 1996). However, MEDENOX study suggested 
that enoxaparin at 20 mg was ineffective for preventing 
VTE in acutely ill medical patients compared to placebo 
(Samama et al 1999).
Enoxaparin 40 mg subcutaneously once daily was shown 
to be as effective as UFH 5000 IU three times daily in the 
PRIME and PRINCE studies (Lechler et al 1996; Kleber 
et al 1998). The PRIME study included various medical 
patients (mean age 74 years), and the PRINCE study included 
patients (mean age 70 years) with severe respiratory disease 
or heart failure.
The recent PREVAIL study was designed to assess the 
efﬁ  cacy and safety of enoxaparin versus UFH for the preven-
tion of VTE in patients with acute ischemic stroke (Sherman 
et al 2007). The mean age of included patients was 66 years, 
and 25% of patients were older than 75 years. More than 
Table 3 Double-blind randomized clinical trials evaluating thromboprophylaxis versus placebo in various medical patients
Author, study, 
year
Treatment Treatment 
duration
Eligible age 
(mean age) 
in years
Number of 
patients
Primary outcome Results: Efﬁ  cacy of 
thromboprophylaxis 
vs placebo
Dahan et al 1986 Enoxaparin 60 mg 
sc od
Until discharge 
or 10 days
65 (80) 270 DVT diagnosed by 125I 
ﬁ  brinogen scanning
DVT: 3% in enoxaparin 
group vs 9.1% 
in placebo group 
(p = 0.03)
Bergmann and 
Caulin 1996 
(Mahe et al 2005)
Nadroparin
0.3 mL sc od
For up to 
21 days
40 (76) 2474 Total mortality at the end 
of the study time, deﬁ  ned 
as 21 days or death.
Mortality: 10.1% in 
nadroparin group 
vs 10.3% in placebo 
group (NS)
Samama et al
MEDENOX 1999
Enoxaparin 40 mg 
sc od Enoxaparin 
20 mg sc od
For 14 days
(mean duration: 7 
days) Follow-up 
110 days
40 (73) 1102 VTE deﬁ  ned as asymp-
tomatic DVT detected 
by bilateral venography 
or ultrasonography or 
symptomatic DVT or 
documented PE
VTE: 15.0% in 
enoxaparin 20 mg 
group vs 14.9% in 
placebo group (NS) 
VTE: 5.5% in enoxa-
parin 40 mg group vs 
14.9% in placebo group 
(p  0.001)
Leizorovicz et al 
PREVENT 2004
Dalteparin 5000 
IU sc od
For 14 days 
Follow-up 
90 days
40 (68.5) 3706 VTE deﬁ  ned as symptom-
atic DVT (proximal or 
distal), fatal or symptom-
atic nonfatal PE, sudden 
death, and asymptomatic 
proximal DVT detected 
by ultrasonography at 
day 21
VTE: 2.8% in dalte-
parin group vs 5.0% 
in placebo group 
(p = 0.0015)
Cohen et al 
ARTEMIS 2006
Fondaparinux
2.5 mg sc od
For 14 days 
(median of 7 days) 
Follow-up 32 days
60 (75) 849 VTE deﬁ  ned as 
symptomatic DVT or PE 
or asymptomatic DVT 
detected by bilateral 
venography
VTE: 5.6% in 
fondaparinux group vs 
10.5% in placebo group 
(p = 0.029)
Lederle 2006 Enoxaparin 
40 mg sc od
Until discharge 
Follow-up 90 days
60 (71.5) 280 Total mortality at 90 days Mortality: 9.3% in 
enoxaparin group 
vs 10% in placebo 
group (NS)Clinical Interventions in Aging 2008:3(3) 405
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90% of patients received a concomitant medication by 
an antiplatelet drug. Enoxaparin was signiﬁ  cantly more 
effective than UFH for the prevention of VTE in patients 
with acute ischemic stroke (RR 0.57, 95% CI 0.44–0.76), 
without signiﬁ  cant difference in terms of bleedings (8% vs 
8%; p = 0.83) or symptomatic intracranial hemorrhage 
(1% vs 1%; p = 0.55).
No studies have directly compared different modalities 
of UFH administration. However, a recent meta-analysis 
comparing UFH given twice daily or 3 times daily from 
12 studies found no difference in the overall rate (per 1000 
patient-days) of VTE (twice daily: 5.4 vs 3 times daily: 3.5; 
p = 0.87), but an increased risk of major bleedings with three 
times daily heparin (twice daily: 0.35 vs 3 times daily: 0.96; 
p  0.001) (King et al 2007).
In regards to the risk of heparin-induced thrombocytopenia 
(HIT) that should be considered when providing patients 
with thromboprophylaxis, LWMHs appeared safer than 
UFH in surgical patients (Warkentin et al 1995). How-
ever, in the recent meta-analysis by Wein and colleagues 
(2007), no statistically signiﬁ  cant differences were observed 
between UFH and LMWH with respect to thrombocytopenia 
(RR, 0.25; 95% CI, 0.05–1.16).
Cost effectiveness analyses
Several studies conducted in different countries have 
evaluated the cost effectiveness of LMWH relative to UFH 
or to no pharmacological prophylaxis for DVT prevention 
in medical inpatients (Lamy et al 2002; Nuijten et al 2002; 
McCarry et al 2004; Schadlich et al 2006; Shorr et al 2007). 
Regardless of some methodological differences, they 
conclude that, despite higher acquisition costs, LMWHs 
for thromboprophylaxis in medical patients resulted in sav-
ings compared to no pharmacological prophylaxis and were 
associated with lower costs or at least neutral cost compared 
with UFH.
To conclude, based on the results of the clinical trials 
presented above, elderly patients hospitalized for an acute 
medical illness should receive a prophylactic anticoagulant 
treatment unless there is a contraindication. LMWHs, 
enoxaparin at the dose of 40 mg and dalteparin at the dose 
of 5000 IU, are effective and safe to prevent VTE in elderly 
patients. Compared to UFH, they are more convenient, 
requiring only one subcutaneous injection daily. They are 
associated with a lower risk of heparin-induced thrombocy-
topenia, and ﬁ  nally are equal or superior in cost effectiveness 
analyses. In case of severe alteration of renal function how-
ever, the safety of LMWHs is uncertain and UFH should be 
considered. More data are needed to recommend the use of 
fondaparinux as a routine treatment in elderly patients. In 
case of contraindication to heparins, graduated stockings or 
intermittent pneumatic compression should be used.
For how long should the treatment be given?
In the main randomized trials, prophylactic treatment was 
given for 1 to 2 weeks. While no speciﬁ  c recommendations 
exist regarding the duration of anticoagulant treatment, treat-
ment would therefore not exceed this length. However, some 
elements could be discussed in favor of duration extension in 
medical patients, and especially in elderly medical patients.
First, it is likely that the thrombotic process has already 
started in some patients before their admission to hospital. In 
a study evaluating the prevalence of VTE in medical patients 
hospitalized for another reason than VTE, asymptomatic 
VTE at admission was diagnosed in 17.8% of patients over 
80 years (Oger et al 2002).
Second, in the MEDENOX, PREVENT and ARTEMIS 
studies, additional symptomatic VTE events and fatal PE 
occurred after discontinuation of prophylaxis during the 
follow up period in the treatment groups (Samama et al 1999; 
Leizorovicz et al 2004; Cohen et al 2006).
Third, extension of prophylaxis duration was shown 
to be effective in other settings. In major orthopedic 
surgery, a meta-analysis of randomized trials conﬁ  rmed 
that prolonged prophylaxis with LWMH for one month 
postoperatively, compared with the standard practice of 
prescribing prophylaxis for 7–10 days, reduced the relative 
risk of all DVT events by 59% (p  0.001), and reduced 
the risk of symptomatic VTE by 64% (p  0.001), without 
increasing bleeding complications (Hull et al 2001). Beneﬁ  t 
of prolonged prophylaxis to 25–31 days was also demon-
strated in patients with active cancer who were undergoing 
surgery (Berqvist et al 2002).
The Extended Clinical Prophylaxis in Acutely III Medical 
Patients (EXCLAIM) trial was designed to demonstrate the 
superiority of extended-duration prophylaxis with enoxaparin 
(28 ± 4 days) compared with the standard regimen of 
enoxaparin (10 ± 4 days) for prevention of VTE in acutely 
ill medical patients with recent reduced mobility (Hull et al 
2007). Mean age of included patients was 70 years, with 
more than 40% of patients being 75 years or older. Extended-
duration prophylaxis with enoxaparin was more effective 
than standard regimen of enoxaparin on the primary efﬁ  cacy 
endpoint (asymptomatic DVT detected by ultrasonography, 
symptomatic DVT, symptomatic PE, fatal PE) (2.8% vs 4.9%, 
RR 0.56, 95% CI 0.39–0.80). However, major hemorrhagic Clinical Interventions in Aging 2008:3(3) 406
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complications occurred signiﬁ  cantly more frequently with the 
extended-duration prophylaxis (0.60% vs 0.15%, RR 4.03; 
95% CI 1.14–14.3) (Hull et al 2007).
One or two weeks is the common duration of prophylactic 
treatment with LMWH or UFH. Extension of prophylaxis 
duration to one month appeared to be more effective than 
standard duration but was also associated with an excess of 
major bleedings. Awaiting further analyses of the EXCLAIM 
study, extended-duration prophylaxis in medical patients 
should be discussed on a case-by-case basis.
Is a monitoring of pharmacological 
prophylaxis required?
The highest risk of anticoagulant prophylaxis is bleeding. 
Even if major bleedings are less frequent with prophylactic 
than with therapeutic doses, physicians should be aware 
of this risk, and should observe their patients regularly 
by clinical examination for all potential bleedings. More-
over, underlying conditions or associated treatments could 
change during hospitalization, and this could increase the 
bleeding risk associated with thromboprophylaxis. A regular 
reassessment of the beneﬁ  t and risk of thromboprophylaxis 
decided on admission should be performed taking into 
account the potential modiﬁ  cations since admission, for 
example, the modiﬁ  cations of renal function or the presence 
of a newly diagnosed contraindication. However, no speciﬁ  c 
biological monitoring is needed to evaluate the anticoagulant 
activity of UFH or LMWH at prophylactic doses.
Less frequent, but often fatal, is the potential development 
of HIT. Even if HIT appeared to be less frequently observed 
with LMWH than with UFH, a monitoring of platelets count 
is required at least twice weekly for all heparins during the 
treatment period (Warkentin and Greinacher 2004).
Regular assessment of bleeding risk associated with 
thromboprophylaxis should be performed, taking into 
account the potential changes in underlying conditions and 
associated treatments. A monitoring of platelets count is 
required for UFH as well as for LMWH.
A proposition of management of thromboprophylaxis in 
elderly medical patients is resumed in Figure 1.
First step: Assessment of VTE risk
Does the patient has one of the following 
acute medical illness? 
Acute myocardial infarction
Acute heart failure
Active cancer requiring therapy
Acute rheumatological disease
Ischemic stroke
Paraplegia
Fifth step: Don’t forget the monitoring: 
Watch over platelets count at least twice 
weekly
Reassess the risk of thromboprophylaxis 
in case of modifications of underlying 
conditions 
Fourth step: LMWH can not be used: 
UFH 5000 IU subcutaneous 2 or 3 times 
daily
Consider mechanical prophylaxis: 
Graduated stockings or intermittent 
pneumatic compression 
No evidence for the benefit of a 
thromboprophylaxis 
First step: Assessment of VTE ri sk
acute medical illness? 
Acute myocardial infarction
Acute heart failure
Active cancer requiring therapy
Acute rheumatological disease
Ischemic stroke
Paraplegia
Third step: Is there a contraindication to 
LMWH? 
Check the creatinine level and estimate the 
creatinine clearance 
First step: Assessment of VTE risk
Does the patient have one of the after 
acute medical illnesses? 
Acute myocardial infarction
Acute heart failure
Active cancer requiring therapy
Acute infectious disease
Respiratory disease
Acute rheumatologic disease
Ischemic stroke
Paraplegia
Inflammatory disorder with immobility 
Inflammatory bowel disease
Second step: Is there a contraindication 
to pharmacological thromboprophylaxis?
Assessment of baseline bleeding risk, history 
of heparin induced thrombocytopenia or 
heparin hypersensitivity, check platelets 
count
Fourth step: LMWH can be used: 
Enoxaparin 40 mg subcutaneous once daily
or dalteparin 5000 IU subcutaneous once 
daily for 1–2 weeks
YES
NO
NO
YES
YES
NO
Figure 1 Management of thromboprophylaxis in elderly (75 years) medical patients.Clinical Interventions in Aging 2008:3(3) 407
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Why is thromboprophylaxis 
in the elderly not better adopted 
in clinical practice?
The gap between theory and practice
Despite available data, and recommendations for VTE 
prevention in medical patients, underuse or misuse of throm-
boprophylaxis remains a problem. A case series study showed 
that among 208 patients who developed acute VTE during 
hospitalization in medical wards, only 48% had received VTE 
prophylaxis (Goldhaber et al 2000). Recently, the Canadian 
CURVE study aimed to determine the proportion of hos-
pitalized, acutely ill medical patients who were eligible to 
receive thromboprophylaxis, and to evaluate the frequency, 
determinants and appropriateness of its use (Kahn et al 
2007). Following ACCP guidelines, authors found that of 
the 1894 medical hospitalized patients who were eligible for 
study inclusion, 90% should receive a thromboprophylaxis. 
However, only 23% received a prophylaxis, and only 16% 
received an appropriate thromboprophylaxis.
Use of prophylaxis in elderly medical patients is unknown, 
but thought to be as low as in general medical patients. 
Nevertheless, in CURVE study, age was not found as a 
determinant of thromboprophylaxis use (Kahn et al 2007), 
and in IMPROVE study, prophylaxis with LMWH or UFH 
was more likely to be used if patients were aged 85 years 
(Tapson et al 2007). In the study by Chopard and colleagues 
(2005), patients treated by thromboprophylaxis were older 
than those without prophylaxis. The rate of patients needing 
thromboprophylaxis and not receiving it was lower for older 
patients (75 years) than for younger patients. However, the 
rate of patients not needing thromboprophylaxis and receiving 
it was higher for older patients than for younger patients.
Explaining the gap
The gap between theory and practice for the use of 
thromboprophylaxis could be explained by many reasons. 
Heterogeneity of clinical studies, selected populations, 
concern about bleedings, and the lack of a clear clinical 
beneﬁ  t are some of these reasons.
Heterogeneity of clinical trials
Clinical trials highlighted the beneﬁ  t of pharmacological 
treatment for VTE prevention in medical patients (Samama 
et al 1999; Leizorovicz et al 2004; Cohen et al 2006). 
However, the different rates of VTE incidence from 
4.8% to 14.9% in the placebo groups suggested disparities 
between studies. This may reﬂ  ect the heterogeneous medical 
conditions of the different populations studied, as well as 
differences in the endpoints and outcomes measure. In fact, 
any study could be directly compared to another. When 
two studies shared the same inclusion criteria, treatments 
and/or primary end points and/or modalities to measure the 
outcomes were different.
As presented in Table 2, eligibility criteria of clinical 
trials, and the resulting validated indications of thrombopro-
phylaxis evaluated in these trials are various and different 
between studies. Compared to surgical settings, there is a lack 
of legibility of eligibility criteria for the use of thrombopro-
phylaxis in medical settings. This complexity is discouraging 
and could explain its underuse.
Homogenization of outcomes definition, outcomes 
measure and simpliﬁ  cation of eligibility criteria are probably 
needed for further trials. This may help to clarify the recom-
mendations and to improve the practice.
Selected medical populations, and probably
high selected elderly populations
Inclusion and exclusion criteria of clinical trials lead to 
selected populations, and results should be interpreted with 
caution before being extrapolated to a larger population. 
Taking into account the high proportion of patients 
hospitalized in medical wards, the number of patients 
included in the clinical trials was low. In IMPROVE, only 
13%–19% of all patients would have been eligible for 
inclusion in MEDENOX, PREVENT, or ARTEMIS studies 
(Anderson et al 2003). This problem can be also illustrated 
by the results of the CURVE study (Kahn et al 2007). Over 
the 3-week study period, in 29 hospitals across Canada, 
1702 medical patients had an indication of thromboprophy-
laxis. This number is higher than the number of included 
patients in MEDENOX study over 18 months in 60 centers 
from nine countries.
Furthermore, many patients who were usually hospital-
ized in geriatric units, were unable to sign a written informed 
consent, presented alteration of renal function or low weight 
were excluded from these trials. Renal insufﬁ  ciency and low 
weight, two frequent conditions in elderly patients and associ-
ated with higher risk of bleeding (Lopez-Jimenez et al 2006), 
were often exclusion criteria. Therefore, selection of a popu-
lation with low risk of bleeding in clinical trials was likely 
and concern about bleeding with thromboprophylaxis could 
be a reason of its underuse in elderly patients. Moreover, as 
an informed consent is required, patients need to understand 
and approve the enrolment in the study. Unfortunately, only 
few patients among the oldest are able to give such consent, Clinical Interventions in Aging 2008:3(3) 408
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because of impairment of cognitive functions, or too severe 
weakness to be able to participate.
Despite ﬁ  ndings of clinical trials suggesting that thrombo-
prophylaxis is effective and safe in the elderly patients, few 
trials enrolled speciﬁ  cally geriatric patients. Additionally, 
elderly patients were probably highly selected and therefore 
not representative of overall elderly medical patients.
Lack of evident clinical beneﬁ  t?
Only few trials were conducted using symptomatic VTE 
and/or mortality as the primary end point. In the majority of 
clinical trials, the primary end point was a combined outcome 
including symptomatic VTE (DVT and/or fatal and non 
fatal PE) and asymptomatic DVT systematically assessed at 
the end of the treatment period. Asymptomatic DVT, however, 
were the great majority of events detected during the studies. 
In medical patients, there is a lack of evidence that prophylaxis 
prevents clinically important outcomes, such as PE, which has 
been shown in surgical patients (Collins et al 1988). Therefore, 
some could argue about the clinical relevance of the results 
from trials conducted in medical settings.
A recent meta-analysis aimed to evaluate the effects of 
anticoagulant prophylaxis in reducing clinically important 
VTE outcomes in hospitalized medical patients (Dentali et al 
2007). Prophylaxis (with UFH, LMWH or fondaparinux) was 
associated with a signiﬁ  cant reduction of any PE (RR: 0.43, 
CI, 0.26–0.71) and fatal PE (RR: 0.38, CI, 0.21–0.69), 
a nonsignificant reduction in symptomatic DVT and a 
nonsigniﬁ  cant increase in major bleeding. Anticoagulant 
prophylaxis had no effect on all-cause mortality. However, 
the main limitation of this analysis is that the results con-
cerned only the treatment period. How are they maintained 
after the treatment has been stopped (which is really the 
relevant question) is unknown.
The beneﬁ  t of  prophylaxis in medical patients is uncertain 
for clinical nonfatal VTE events, and no beneﬁ  t on overall 
mortality was demonstrated. How these results are relevant 
for elderly population remains to be determined.
Challenges to improve the practice
As life expectancy is increasing in developed countries, 
incidence of   VTE is also expected to increase. How to 
prevent this potential fatal disease will arise as a major public 
health problem for the next decades. According to the Agency 
for Healthcare Research and Quality in the United States, 
prevention of  VTE in adult patients in hospital was the main 
challenge to patient safety in 2001 (Agency for Healthcare 
Research and Quality 2001).
Therefore, many efforts have to be done to improve 
thromboprophylaxis particularly in the elderly. Determining 
the optimal strategy of prevention is essential and further trials 
conducted speciﬁ  cally in the elderly nonselected patients 
and evaluating the beneﬁ  t-risk ratio of thromboprophylaxis 
are needed. However, available results suggested that some 
prophylactic treatments were effective and safe even in the 
older patients. These treatments should be more used in 
practice following the available guidelines. But the use of 
such treatments in the “real life” and for patients that would 
have not been included in the clinical trials must be evaluated. 
Reducing the gap between theory and practice shown by many 
studies should reduce the number of patients exposed to high 
risk of thrombosis and not receiving effective prevention.
To improve practice, some suggestions should be 
proposed in all hospitals:
•  Results of epidemiologic studies highlighted the 
importance of   VTE in in-hospital morbi-mortality 
should be largely taught. This would reduce the lack of 
awareness that VTE is a real public health problem among 
all practitioners.
•  Models of assessment of the VTE risk should be vali-
dated and more used. Assessment of the risk of VTE 
for all medical patients is the ﬁ  rst recommendation of 
current guidelines (Nicolaides et al 2001; Geerts et al 
2004). However, assessing the individual risk of VTE 
in medical settings is difﬁ  cult. Models to assess this risk 
have been developed to assist the physicians to determine 
if thromboprophylaxis is warranted or not (Samama et al 
2003, 2006; Cohen et al 2005). But these models have 
not been validated in speciﬁ  cally designed prospective 
clinical trials, they are less structured than in surgical 
settings and are not conceived for elderly patients. 
Nevertheless, systematic assessment of   VTE risk at 
admission has been shown to improve the prophylaxis 
practice in an original initiative conducted in Brigham 
and Women’s Hospital in Boston (Kucher et al 2005a). 
A computer program linked to the patient database was 
developed to identify consecutive hospitalized patients 
at risk for DVT in the absence of prophylaxis. Eligible 
patients were randomly assigned to an intervention 
group, in which the responsible physician was alerted 
to a patient’s risk of DVT, and to a control group, in 
which no alert was issued. The computer alert reduced 
the risk of VTE at 90 days by 41% (HR, 0.59; 95% CI, 
0.43–0.81). These encouraging ﬁ  ndings suggested that 
alerting physicians to the individual risk of VTE could 
contribute to improve the rate of clinical outcomes.Clinical Interventions in Aging 2008:3(3) 409
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•  Regular updates on prevention of  VTE in medical settings 
should also be proposed in Continuing Medical Education 
programs. On these occasions, last data and last recom-
mendations of experts could be presented and discussed.
Finally, further studies are needed to determine the 
place of the new anticoagulant drugs, such as direct Factor 
Xa inhibitors or antithrombin inhibitors, in the prevention 
of VTE in medical settings. Besides their effectiveness and 
safety demonstrated in surgical settings, their pharmacoki-
netic properties (that allow one oral daily dose) provide other 
advantages that should be useful in daily practice.
Conclusions
Elderly patients are the most concerned by VTE, and develop-
ment of optimal thromboprophylaxis strategies should be a 
priority in this population. Further clinical trials evaluating 
efﬁ  cacy and risk of thromboprophylactic methods, including 
new anticoagulant drugs, are needed for elderly patients. 
Awaiting such trials, and despite some limitations, available 
data from existing clinical trials conducted in hospitalized 
medical patients supported a good beneﬁ  t-risk ratio of dif-
ferent thromboprophylaxis modalities in geriatric patients. 
Nevertheless, in practice, the balance between expected 
beneﬁ  t and risk of prophylactic anticoagulation should be 
carefully assessed for each individual elderly patient taking 
into account the speciﬁ  c risk of VTE in older patients and 
the risk of anticoagulant related bleeding probably underes-
timated in clinical trials. Risk assessment models developed 
for overall medical patients are useful tools to improve the use 
of thromboprophylaxis even in elderly patients, but remain 
to be evaluated in this speciﬁ  c population.
Disclosures
DM and KL were investigators for the EXCLAIM study. DM, 
KL, and GLG were investigators in clinical trials evaluating 
new antithrombotic drugs (Sanoﬁ   Aventis, GSK, Boehringer, 
Léo, Bayer, BMS). None have stock holdings or options. 
None received salaries.
References
Agency for Healthcare Research and Quality. 2001. Making health care 
safer. A critical analysis of patient safety practices: summary [online]. 
Evidence Report/Technology Assessment Number 43. Rockville, MD: 
AHRQ, www.ahrq.gov/clinic/ptsafety/summary.htm.
Alikhan R, Cohen AT, Combe S,et al. 2003. Prevention of venous 
thromboembolism in medical patients with enoxaparin: a subgroup 
analysis of the MEDENOX study. Blood Coagul Fibrinolysis, 
14:341–6.
Alikhan R, Cohen AT, Combe S, et al. 2004. Risk factors for venous throm-
boembolism in hospitalized patients with acute medical illness: analysis 
of the MEDENOX Study. Arch Intern Med, 164:963–8.
Anderson FA Jr, Decousus H, Bergmann JF, et al. 2003. A multinational 
observational cohort study in hospitalized medical patients of practices 
in prevention of venous thromboembolism and clinical outcomes: 
ﬁ  ndings of the International Medical Prevention Registry of Venous 
Thromboembolism (IMPROVE). J Thromb Haemost, 1:1438.
Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. 1991. A population-based 
perspective of the hospital incidence and case-fatality rates of deep vein 
thrombosis and pulmonary embolism. The Worcester DVT Study. Arch 
Intern Med, 151:933–8.
Arcelus JI, Caprini JA, Monreal M et al. 2003. The management and 
outcome of acute venous thromboembolism: a prospective registry 
including 4011 patients. J Vasc Surg, 38: 916–22.
Baglin TP, White K, Charles A. 1997. Fatal pulmonary embolism in hos-
pitalised medical patients. J Clin Pathol, 50:609–10.
Belch JJ, Lowe GD, Ward AG, et al. 1981. Prevention of deep vein throm-
bosis in medical patients by low-dose heparin. Scott Med J, 26:115–7.
Bergmann JF, Caulin C. 1996. Heparin prophylaxis in bedridden patients. 
Lancet, 348:205–6.
Bergmann JF, Neuhart E. 1996. A multicenter randomized double-blind 
study of enoxaparin compared with unfractionated heparin in the 
prevention of venous thromboembolic disease in elderly in-patients 
bedridden for an acute medical illness. The Enoxaparin in Medicine 
Study Group. Thromb Haemost, 76:529–34.
Bergqvist D, Agnelli G, Cohen AT, et al. ENOXACAN II Investigators. 
2002. Duration of prophylaxis against venous thromboembolism with 
enoxaparin after surgery for cancer. N Engl J Med, 346:975–80.
Beyth RJ, Quinn LM, Landefeld CS. 1998. Prospective evaluation of an 
index for predicting the risk of major bleeding in outpatients treated 
with warfarin. Am J Med, 105:91–9.
Cade JF, Andrews JT, Stubbs AE.1982. Comparison of sodium and calcium hepa-
rin in prevention of venous thromboembolism. Aust NZ J Med, 12:501–4.
Campbell NR, Hull RD, Brant R, et al. 1996. Aging and heparin-related 
bleeding. Arch Intern Med, 156:857–60.
Chopard P, Dorfﬂ  er-Melly J, Hess U, et al. 2005. Venous thromboembolism 
prophylaxis in acutely ill medical patients: deﬁ  nite need for improve-
ment. J Intern Med, 257:352–7.
Cohen AT, Alikhan R, Arcelus JI, et al. 2005. Assessment of venous throm-
boembolism risk and the beneﬁ  ts of thromboprophylaxis in medical 
patients. Thromb Haemost, 94:750–9.
Cohen AT, Davidson BL, Gallus AS, et al. ARTEMIS Investigators. 2006. 
Efﬁ  cacy and safety of fondaparinux for the prevention of venous 
thromboembolism in older acute medical patients: randomised placebo 
controlled trial. BMJ, 332:325–9.
Collins R, Scrimgeour A, Yusuf  S, et al. 1988. Reduction in fatal pulmonary 
embolism and venous thrombosis by perioperative administration of 
subcutaneous heparin. Overview of results of randomized trials in gen-
eral, orthopedic, and urologic surgery. N Engl J Med, 318:1162–73.
Dahan R, Houlbert D, Caulin C, et al. 1986. Prevention of deep vein throm-
bosis in elderly medical in-patients by a low molecular weight heparin: 
a randomized double-blind trial. Haemostasis, 16:159–64.
Dentali F, Douketis JD, Gianni M, et al. 2007. Meta-analysis: anticoagulant 
prophylaxis to prevent symptomatic venous thromboembolism in hos-
pitalized medical patients. Ann Intern Med, 146:278–88.
Fraisse F, Holzapfel L, Couland JM, et al. 2000. Nadroparin in the prevention 
of deep vein thrombosis in acute decompensated COPD. The Associa-
tion of Non-University Afﬁ  liated Intensive Care Specialist Physicians 
of France. Am J Respir Crit Care Med, 161:1109–14.
Gardlund B. 1996. Randomised, controlled trial of low-dose heparin for 
prevention of fatal pulmonary embolism in patients with infectious dis-
eases. The Heparin Prophylaxis Study Group. Lancet, 347:1357–61.
Geerts WH, Pineo GF, Heit JA, et al. 2004. Prevention of venous 
thromboembolism: the Seventh ACCP Conference on Antithrombotic 
and Thrombolytic Therapy. Chest, 126:338–400.
Goldhaber SZ, Dunn K, MacDougall RC. 2000. New onset of venous 
thromboembolism among hospitalized patients at Brigham and 
Women’s Hospital is caused more often by prophylaxis failure than 
by withholding treatment. Chest, 118:1680–4.Clinical Interventions in Aging 2008:3(3) 410
Lacut et al
Goldhaber SZ, Savage DD, Garison RJ, et al. 1983. Risk factors for 
pulmonary embolism: the Farmingham Study. Am J Med, 74:1023–8.
Heit JA, O’Fallon WM, Petterson TM, et al. 2002. Relative impact of 
risk factors for deep vein thrombosis and pulmonary embolism. 
A population-based study. Arch Intern Med, 162:1245–8.
Heit JA, Silverstein MD, Mohr DN, et al. 2000. Risk factors for deep vein 
thrombosis and pulmonary embolism: a population-based case-control 
study. Arch Intern Med, 160:809–15.
Heit JA, Silvestein MD, Mohr DN, et al. 2001. The epidemiology of venous 
thromboembolism in the community. Thromb Haemost, 86:452–63.
Hull RD, Pineo GF, Stein PD, et al. 2001. Extended out-of-hospital low-
molecular-weight heparin prophylaxis against deep venous thrombosis 
in patients after elective hip arthroplasty: a systematic review. Ann 
Intern Med, 135:858–69.
Hull RD, Schellong SM, Tapson VF, et al. 2007. Extended-duration venous 
thromboembolism prophylaxis in acutely ill medical patients with 
recent reduced mobility: the EXCLAIM study. J Thromb Haemost, 
5:O-S-001.
Ibarra-Pérez C, Lau-Cortés E, Colmenero-Zubiate S, et al. 1988. Prevalence 
and prevention of deep venous thrombosis of the lower extremities in 
high-risk pulmonary patients. Angiology, 39:505–13.
Kahn SR, Panju A, Geerts W, et al. CURVE Study Investigators. 2007. 
Multicenter evaluation of the use of venous thromboembolism prophylaxis 
in acutely ill medical patients in Canada. Thromb Res, 119:145–55.
Kakkar AK, Levine MN, Kadziola Z, et al. 2004. Low molecular weight 
heparin, therapy with dalteparin, and survival in advanced cancer: the 
Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin 
Oncol, 22:1944–8.
Kamphuisen PW, Agnelli G. 2007. What is the optimal pharmacological 
prophylaxis for the prevention of deep-vein thrombosis and pulmonary 
embolism in patients with acute ischemic stroke? Thromb Res, 
119:265–74.
King CS, Holley AB, Jackson JL, et al. 2007. Twice vs three times daily 
heparin dosing for thromboembolism prophylaxis in the general medical 
population: A meta-analysis. Chest, 131:507–16.
Kleber FX, Witt C, Flosbach CW, et al. PRINCE Study Group. 1998. 
Study to compare the efﬁ  cacy and safety of the LMWH Enoxaparin 
and standard heparin in the prevention of thromboembolic events 
in medical patients with cardiopulmonary diseases. Ann Hematol, 
76:261.
Knifﬁ  n WD Jr, Baron JA, Barrett J, et al. 1994. The epidemiology of 
diagnosed pulmonary embolism and deep venous thrombosis in the 
elderly. Arch Intern Med, 154:861–6.
Kucher N, Koo S, Quiroz R, et al. 2005a. Electronic alerts to prevent 
venous thromboembolism among hospitalized patients. N Engl J Med, 
352:969–77.
Kucher N, Leizorovicz A, Vaitkus PT, et al. 2005b. Efﬁ  cacy and safety 
of ﬁ  xed low-dose dalteparin in preventing venous thromboembolism 
among obese or elderly hospitalized patients: a subgroup analysis of 
the PREVENT trial. Arch Intern Med, 165:341–5.
Lamy A, Wang X, Kent R, et al. 2002. Economic evaluation of the 
MEDENOX trial: a Canadian perspective. Can Respir J, 9:169–77.
Landefeld CS, Beyth RJ. 1993. Anticoagulant related bleeding: clinical 
epidemiology, prediction and prevention. Am J Med, 95:315–28.
Le Gal G, Righini M, Roy PM, et al. 2005. Differential value of risk factors 
and clinical signs for diagnosing pulmonary embolism according to age. 
J Thromb Haemost, 3:2457–64.
Lechler E, Schramm W, Flosbach CW; The PRIME Study Group. 1996. The 
venous thrombotic risk in nonsurgical patients: epidemiologal data and 
efﬁ  cacy/safety proﬁ  le of a low molecular weight heparin (enoxaparin). 
Haemostasis, 26:49–56.
Lederle FA, Sacks JM, Fiore L, et al. 2006. The prophylaxis of medical 
patients for thromboembolism pilot study. Am J Med, 119:54–9.
Leizorovicz A, Cohen AT, Turpie AG, et al. PREVENT Medical Throm-
boprophylaxis Study Group. 2004. Randomized, placebo-controlled 
trial of dalteparin for the prevention of venous thromboembolism in 
acutely ill medical patients. Circulation, 110:874–9.
Levine M, Hirsh J, Gent M, et al. 1994. Double-blind randomised trial of 
a very-low-dose warfarin for prevention of thromboembolism in stage 
IV breast cancer. Lancet, 343:886–9.
Levine MN, Raskob G, Landefeld S, et al. 2001. Hemorrhagic complications 
of anticoagulant treatment. Chest, 119:108–21.
Lindblad B, Sternby NH, Bergqvist D. 1991. Incidence of venous thrombo-
embolism veriﬁ  ed by necropsy over 30 years. Br Med J, 302:709–11.
Lopez-Jimenez L, Montero M, Gonzalez-Fajardo JA, et al. RIETE 
Investigators. 2006. Venous thromboembolism in very elderly 
patients: ﬁ  ndings from a prospective registry (RIETE). Haematologica, 
91:1046–51.
Mahe I, Bergmann JF, d’Azemar P, et al. 2005. Lack of effect of a low-
molecular-weight heparin (nadroparin) on mortality in bedridden 
medical in-patients: a prospective randomised double-blind study. Eur 
J Clin Pharmacol, 61:347–51.
McGarry LJ, Thompson D, Weinstein MC, et al. 2004. Cost effectiveness 
of thromboprophylaxis with a low-molecular-weight heparin versus 
unfractionated heparin in acutely ill medical inpatients. Am J Manag 
Care, 10:632–42.
Mismetti P, Laporte-Simitsidis S, Tardy B, et al. 2000. Prevention of 
venous thromboembolism in internal medicine with unfractionated or 
low-molecular-weight heparins: a meta-analysis of randomised clinical 
trials. Thromb Haemost, 83:14–9.
Monreal M, Kakkar AK, Caprini JA, et al. The RIETE Investigators. 2004. 
The outcome after treatment of venous thromboembolism is different 
in surgical and acutely ill medical patients. Findings from the RIETE 
registry. J Thromb Haemost, 2:1892–8.
Nicolaides AN, Breddin HK, Fareed J, et al. 2001. Prevention of venous throm-
boembolism. International Consensus Statement. Guidelines compiled in 
accordance with the scientiﬁ  c evidence. Int Angiol, 20:1–37.
Nuijten MJ, Berto P, Kosa J, et al. 2002. Cost-effectiveness of enoxaparin 
as thromboprophylaxis in acutelly ill medical patients from the Italian 
NHS perspective. Recenti Prog Med, 93:80–91.
Oger E. EPI-GETBO Study Group. 2000. Incidence of venous throm-
boembolism: a community-based study in Western France. Thromb 
Haemost, 83:657–60.
Oger E, Bressolette L, Nonent M, et al. 2002. High prevalence of asymptom-
atic deep vein thrombosis on admission in a medical unit among elderly 
patients. The TADEUS Project. Thromb Haemost, 88:592–7.
Pitt A, Anderson ST, Habersberger PG, et al. 1980. Low dose heparin in the 
prevention of deep-vein thromboses in patients with acute myocardial 
infarction. Am Heart J, 99:574–8.
Righini M, Goehring C, Bounameaux H, et al. 2000. Effects of age on the 
performance of common diagnostic tests for pulmonary embolism. 
Am J Med, 109:357–61.
Righini M, Le Gal G, Perrier A, et al. 2005. The challenge of diagnosing 
pulmonary embolism in elderly patients: inﬂ  uence of age on commonly 
used diagnostic tests and strategies. J Am Geriatr Soc, 53:1039–45.
Rosendaal FR. 1999. Venous thrombosis: a multicausal disease. Lancet, 
353:1167–73.
Samama MM, Cohen AT, Darmon JY, et al. 1999. A comparison of 
enoxaparin with placebo for the prevention of venous thromboembolism 
in acutely ill medical patients. Prophylaxis in Medical Patients with 
Enoxaparin Study Group. N Engl J Med, 341:793–800.
Samama MM, Dahl OE, Mismetti P, et al. 2006. An electronic tool for 
venous thromboembolism prevention in medical and surgical patients. 
Haematologica, 91:64–70.
Samama MM, Dahl OE, Quinlan DJ, et al. 2003. Quantification of 
risk factors for venous thromboembolism: a preliminary study 
for the development of a risk assessment tool. Haematologica, 
88:1410–21.
Samama MM. 2000. An epidemiologic study of risk factors for deep vein 
thrombosis in medical outpatients: the SIRIUS study. Arch Intern 
Med, 160:3415–20.
Sandler DA, Martin JF.1989. Autopsy proven pulmonary embolism in 
hospital patients: are we detecting enough deep vein thrombosis? 
J R Soc Med, 82:203–5.Clinical Interventions in Aging 2008:3(3) 411
VTE prophylaxis in elderly patients
Schadlich PK, Kentsch M, Weber M, et al. 2006. Cost effectiveness of 
enoxaparin as prophylaxis against venous thromboembolic complica-
tions in acutely ill medical inpatients: modelling study from the hospital 
perspective in Germany. Pharmacoeconomics, 24:571–91.
Sherman DG, Albers GW, Bladin C, et al. PREVAIL Investigators. 2007. 
The efﬁ  cacy and safety of enoxaparin versus unfractionated heparin 
for the prevention of venous thromboembolism after acute ischaemic 
stroke (PREVAIL Study): an open-label randomised comparison. 
Lancet, 369:1347–55.
Shorr AF, Jackson WL, Weiss BM, et al. 2007. Low-molecular weight 
heparin for deep vein thrombosis prophylaxis in hospitalized medical 
patients: results from a cost-effectiveness analysis. Blood Coagul 
Fibrinolysis, 18:309–16.
Tapson VF, Decousus H, Pini M, et al. IMPROVE Investigators. 2007. 
Venous thromboembolism prophylaxis in acutely ill hospitalized 
medical patients: ﬁ  ndings from the International Medical Prevention 
Registry on Venous Thromboembolism. Chest, 132:936–45.
Warkentin TE, Greinacher A. 2004. Heparin-induced thrombocytopenia: 
recognition, treatment, and prevention. The Seventh ACCP Conference 
on Antithrombotic and Thrombolytic Therapy. Chest, 126:311–37.
Warkentin TE, Levine MN, Hirsh J, et al. 1995. Heparin-induced throm-
bocytopenia in patients treated with low-molecular-weight heparin or 
unfractionated heparin. N Engl J Med, 332:1330–5.
Wein L, Wein S, Haas SJ, et al. 2007. Pharmacological venous thromboem-
bolism prophylaxis in hospitalized medical patients. A meta-analysis of 
randomized controlled trials. Arch Intern Med, 167:1476–86.
White RH, Beyth RJ, Zhou H, et al. 1999. Major bleeding after 
hospitalization for deep-venous thrombosis. Am J Med, 107:414–24.